

96/6/98
010 PRO

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Anticipated Classification
of this Application:
Class _____ Subclass _____

Prior Application:
Exam'r: Remy Yucel
Group Art Unit: 1805

Attorney's
Docket No.:
Enz-53 (DIV 3)

FILED BY EXPRESS MAIL

Hon. Commissioner of Patents and Trademarks
Washington, D.C. 20231
BOX FWC (if under 1.62)

#2/PN-A
J.R
02/25/98

Sir:

This is a request for filing a CONTINUATION DIVISIONAL
CONTINUATION-IN-PART application under 37 CFR 1.60
37 CFR 1.62, of pending prior application Serial No. 08/574,443
filed on December 15, 1995 of Elazar Rabbani et al.
Inventor(s)

for:

**NOVEL PROPERTY EFFECTING AND/OR PROPERTY EXHIBITING
COMPOSITIONS FOR THERAPEUTIC AND DIAGNOSTIC USES**

Title of Invention

1. Enclosed is a copy of the prior application, as originally filed and an affidavit or declaration verifying it as a true copy.
2. A copy of the verified statement under 37 CFR 1.9 and 1.27 establishing small entity status in the prior application is enclosed. Small entity status is still applicable.
3. The filing fee is calculated as follows:

CLAIMS AS FILED, LESS ANY CLAIMS CANCELLED BY AMENDMENT								
					RATE		FEE	
	Number Filed		Number Extra		Small Entity	Other Entity	Small Entity	Other Entity
Total Claims	1	=	0	x	\$ 11	\$ 22	=	\$ 395 \$ ---
Independent Claims	1	=	0	x	\$ 41	\$ 82	=	\$ 0 \$ ---
Multiple Dependent Claims Presented:	Yes <input checked="" type="checkbox"/> No				\$ 135	\$ 270		\$ ---
If the difference in Col. 1 is less than zero, enter "0" in Col.2						BASIC FEE		\$ ---
							\$ 395	
						TOTAL FEE		\$ ---
							\$ 395	

EXPRESS MAIL CERTIFICATE

Express Mail Label No. EM44-44-3838
Deposit Date November 25, 1997

I hereby certify that this paper and the attachments
herein are being deposited with the United States
Postal Service "Express Mail Post Office in
Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the Commissioner of
Patents and Trademarks, Washington DC 20231

[Signature] Nov 25 '97
Ronald C. Feltus

Attorney's Docket No. Enz-53 (DIV 3)

Elazar Rabbani et al.
Serial No.: 08/574,443
Filed: Herewith
Page: 2 (Request for a Continuation Application Under 37 C.F.R. 1.60 -
November 25, 1997)

4. The Commissioner is hereby authorized to charge payment of the filing fee as well as the following fees associated with this application or to credit any overpayment to Deposit Account No. 05-1135. A **duplicate** copy of this sheet is enclosed.

Any additional filing fees required under 37 CFR 1.16.

Any patent application processing fees under 37 CFR 1.17.

5. The Commissioner is hereby authorized to charge payment of the following fees during the pendency of this application or credit any overpayment to Deposit Account No. 05-1135. A **duplicate** copy of this sheet is enclosed.

Any patent application processing fees under 37 CFR 1.17.

The issue fee set in 37 CFR 1.18 at or before mailing of the Notice of Allowance, pursuant to 37 CFR 1.311(b).

Any filing fees under 37 CFR 1.16 for presentation of extra claims.

6. A check in the amount of \$ _____ is enclosed.

7. Cancel claims 25-244.

8. Amend the specification by inserting before the first line of the sentence: ---- This is a _____ continuation, divisional, _____ continuation-in-part, of application Serial No. 08/574,443, filed on December 15, 1995. ---

9. Transfer the drawings from the prior application.

10. Informal Formal drawings are enclosed.

11. Abandon said prior application as of the filing date accorded this application. A **duplicate** copy of this sheet is enclosed for filing in the prior application file.

12. Priority of application Serial No. _____ filed on _____ is claimed under 35 U.S.C. 119. _____ The certified copy of the priority application has been filed in prior application Serial No. _____ filed _____.

13. The prior application is assigned of record to Enzo Therapeutics, Inc., c/o Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022. [A copy of the originally submitted Assignment and the Notice of Recordation are enclosed herewith.]

14. A preliminary amendment is enclosed.

Elazar Rabbani et al.
Serial No.: 08/574,443
Filed: Herewith
Page: 3 (Request for a Continuation Application Under 37 C.F.R. 1.60 -
November 25, 1997)

15. X The power of attorney in the prior application is to:
Ronald C. Fedus, Reg. No. 32,567, and John J. Santalone,
Reg No. 32, 794.

(a) X The power appears in the original papers in the prior application.

(b) _____ Since the power does not appear in the original papers, a copy of the power in the prior application is enclosed.

(c) _____ A copy of a new substitute power of attorney is enclosed.

(d) _____ Address all future communications to: (May only be completed by applicant, or attorney or agent of record.)

Ronald C. Fedus, Esq.
Enzo Diagnostics, Inc.
c/o Enzo Biochem, Inc.
527 madison Avenue (9th Floor)
New York, New York 10022

16. X Also accompanying this Request is a Petition to Revive An Unintentionally Abandoned Application Under 37 C.F.R. 1.137(b).

17. X I hereby verify that the attached papers are a true copy of prior application Serial No. 08/574,443.


18. _____ The parent application (Serial No. 08/574,443) was unintentionally abandoned after 2/25/97, which was the date that a response to the 11/25/96 Office Action was originally due. As noted under No. 16 above, this Request For a Continuation Application is accompanying the Petition to Revive an Unintentionally abandoned Application Under 37 C.F.R. 1.137(b), along with the requisite petition fee therefor. With the expected granting of the Petition, the parent application will be copending with the filing of this new continuation application.

The undersigned declares further that all statements made herein of his own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States

Elazar Rabbani et al.
Serial No.: 08/574,443
Filed: Herewith
Page: 4 (Request for a Continuation Application Under 37 C.F.R. 1.60 -
November 25, 1997)

Code and that such willful false statements may jeopardize the validity of the
application or any patent issuing thereon.

Nov 25 97
Date



Signature [Ronald C. Fedus]

Registration No. 32,567

Attorney for Applicants

Inventor(s)

Assignee of Complete Interest

Attorney or Agent of Record

Filed under 37 CFR 1.34(a)

Address of Signator:
Enzo Therapeutics, Inc.
c/o Enzo Biochem, Inc.
527 madison Avenue (9th Floor)
New York, New York 10022

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Commissioner of
Patents and Trademarks
Washington, DC 20231

Box: PATENT APPLICATION

Sir:

Transmitted herewith for filing is the patent application of:

Inventor(s): Elazar Rabbani,
Jannis G. Stavrianopoulos,
James J. Donegan,
Dakai Liu,
Norman E. Kelker, and
Dean L. Engelhardt

For: **NOVEL PROPERTY EFFECTING AND/OR PROPERTY
EXHIBITING COMPOSITIONS FOR THERAPEUTIC &
DIAGNOSTIC USES**

Respectfully submitted,



Ronald C. Fedus
Registration No. 32,567
Attorney for Applicants

DECEMBER 15, 1995

Date

ENZO THERAPEUTICS, INC.
ENZO DIAGNOSTICS, INC.
c/o Enzo Biochem, Inc.
575 Fifth Avenue (18th Floor)
New York, New York 10017
Telephone (212) 856-0876

EXPRESS MAIL CERTIFICATE	
"Express Mail" Label No EF136871946	
Deposit Date DECEMBER 15, 1995	
I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and Trademarks, Washington DC 20231.	
Ronald C. Fedus Reg. No. 32,567	DEC 15 1995 Date